Hara Oyedeji, DNP, PMHNP-BC

Fatigue and poor sleep send patients to primary care, but a CBC and a thyroid panel will not find depression. The panel examines what actually separates major depression from its mimics.

Clinicians outline ways to boost schizophrenia outcomes: team-and-family collaboration, early detection, medication access, measurement-based care.

New rapid-acting and long-acting injectables help bridge hospital-to-community care, cutting post-discharge nonadherence and relapse risk.

Depression rarely arrives named. The panel opens on the presentations that mask it, the risk factors worth flagging in primary care, and the lag between first symptom and adequate treatment.

Clinicians weigh telepsychiatry for schizophrenia, urge early long-acting injectables, and reveal tips on samples, coupons, and prior authorizations.

Inside the ED psychiatric crisis pathway: rapid evaluation, safety triage, long-acting injectables,

Discover how coordinated schizophrenia care teams—clinicians, social supports, and peers—improve communication, housing, work, and quality of life.

Clinicians track relapse risk in schizophrenia by spotting functional decline, paranoia, missed care, and triggers, using family check-ins, brief scales, and labs.

Therapeutic drug monitoring clarifies adherence and plasma levels, while long-acting injectables and patches reduce variability and support patient-centered benefit-risk decisions.

Clinicians weigh oral, LAI and transdermal antipsychotics, urging early use, adherence focus, and side-effect education to optimize outcomes.

This episode, titled "Integrating Novel Mechanisms into Schizophrenia Treatment Practice," features panelist Mark Jankelow discussing the practical clinical considerations surrounding a novel muscarinic agent.

Explore 2024’s xanomeline–trospium: M1/M4 muscarinic therapy for schizophrenia, easing EPS and metabolic risks while raising GI concerns.

Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.

Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.

Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.

Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.